%0 Journal Article
%T Rivaroxaban and early periprostethic joint infection: our experience
%A Alessandro Beltrame
%A Andrea Zangari
%A Araldo Causero
%A Dania De Franceschi
%A Enrico Daniele Di Benedetto
%A Paolo Di Benedetto
%A Renato Gisonni
%A Vanni Cainero
%J Archive of "Acta Bio Medica : Atenei Parmensis".
%D 2017
%R 10.23750/abm.v88i4-S.6792
%X Background and aim of the work: Periprostethic joint infection (PJI) is a severe post-operative complication after Primary Total Hip Arthroplasty (THA). According to the classification of PJI early acute PJI occurs within 4 weeks from surgery. Some authors think that Rivaroxaban is a risk factor in the incidence of early acute PJI. We analyze our experience about this item. Materials and methods: We analyze our experience from 1st January 2015 to 31th December 2016. We consider all consecutive hip arthroplasty implants in this period. Results: In the 205 patients analysed we not find early acute PJI in Rivaroxaban group nor in the others assuming another kind of thromboprophylaxis. Conclusions: In our series there is no evidence of association between Rivaroxaban and early acute PJI. This is a retrospective cohort study, so we need more studies and more robust experimental designs to confirm these results. (www.actabiomedica.it
%K acute early periprostethic joint infection
%K Rivaroxaban
%K Total Hip Arthroplasty
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357653/